相关实验视频
Updated: May 31, 2025

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
9.5K
通过p53/Mdm2通路进行EZETIMIB抗癌活性
Charmy Twala1, Sibusiso Malindisa1, Chamone Munnik1
1Department of Life & Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Cnr. Pioneer and Christiaan de Wet Roads, B2-010 Calabash Building, Florida, Johannesburg 1710, South Africa.
Biomedicines
|January 25, 2025
概括
一种心血管药物Ezetimibe通过抑制Mdm2和癌细胞生长,显示出潜在的抗癌活性. 进一步的研究可能将其与RBBP6抑制剂相结合,以提高疗效.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃泽蒂米布是一种心血管药物,可以抑制尼曼-皮克C1-Like 1 (NPC1CL1) 蛋白.
- 新出现的证据表明,Ezetimibe可能通过降低胆固醇或特定的信号通路具有抗癌特性.
研究的目的:
- 为了研究埃泽蒂米布的潜在抗癌机制.
- 评估埃泽提米布与Mdm2的结合亲和力及其对癌症细胞系的影响.
主要方法:
- 进行了包括分子对接在内的in silico研究,以评估Ezetimibe与Mdm2蛋白质的结合.
- 对比了埃泽提米布和其他抑制剂 (RG7388,RG7112) 的结合能.
- 在不同度下评估了Ezetimibe对癌细胞系生长的影响.
主要成果:
- 埃泽提米布强烈地与Mdm2蛋白的p53结合域结合,形成一个稳定的复合体.
- 与RG7388和RG7112.2相比,ezetimibe的结合能量较低.
- 在对正常细胞无毒的度下,ezetimibe 抑制了多个癌症细胞系的生长.
结论:
- 埃泽比显示出对Mdm2.2过度表达的癌症的潜在疗效.
- 与RBBP6抑制剂的联合治疗可以增强Ezetimibe的抗癌活性.
- 由于口服生物可用性较差,建议在癌症治疗中对Ezetimibe进行管注射.
相关概念视频
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
The Intrinsic Apoptotic Pathway
6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K

